Navigation Links
Human Genome Sciences Announces Positive Final Results Of Phase 2b,Trial of Albuferon

es than the Pegasys treatment group. Among heavier patients (>75 kg) who were treatment-adherent, 71.2% of those in the combined groups receiving Albuferon every two weeks achieved SVR, versus 53.3% for patients receiving Pegasys once a week. The ability to maintain efficacy in heavier patients is of particular importance in certain markets, including the United States, where a large percentage of patients weigh more than 75 kg.

Top-Line Final Results by Treatment Group

The top-line final results of the Phase 2b trial at Week 24 following the completion of therapy include the following SVR rates and other findings:

    Albuferon 900-mcg Every Two Weeks (Albuferon 900 Q2w)


    -- Based on an intention-to-treat (ITT) analysis, 58.5% of patients in the

       Albuferon 900 Q2w treatment group achieved SVR, vs. 57.9% for Pegasys

       administered every week.

    -- In heavier patients (>75 kg) who were treatment-adherent, 74.2% of

       those in the Albuferon 900 Q2w treatment group achieved SVR, versus

       53.3% for Pegasys.

    -- Among all treatment-adherent patients in the Albuferon 900 Q2w

       treatment group, 72.3% achieved SVR, versus 66.7% for Pegasys.

    -- Based on the SF-36 Health Survey, patients in the Albuferon 900 Q2w

       treatment group reported less impairment of health-related quality of

       life, compared with patients in the Pegasys treatment group, as

       measured by both physical component and mental component SF-36 summary

       measures at all time-points throughout the 48-week treatment period.

    -- Fewer working patients in the Albuferon 900 Q2w treatment group

       reported missing 7 days or more of work during the month prior to their

       visits at Weeks 12 and 24, vs. the Pegasys group (Week 12:  3.0% for

       Albuferon 900 Q2w vs. 19.2% for Pegasys; Week 24:  5.8% for Albuferon

       900 Q2w, vs. 22.4% for Pegasys).

    -- The rate of discontinuations due to adverse e
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Testing for Human Papillomavirus
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
4. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
5. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
6. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
7. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
8. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
9. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
10. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
(Date:1/15/2014)... Jan. 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... used on patients in order to treat dental impairments, ...
(Date:1/15/2014)... Texas , Jan. 15, 2014  Novation, the leading ... awarded several new IT value-added reseller (VAR) national contracts ... IT goods and services at lower costs. These include ... services such as initiative assistance and ongoing IT consulting ...
(Date:1/15/2014)... DUBLIN , January 15, 2014 Shire plc ... waived the Office of Fair Trading (OFT) approval condition to the ... Incorporated (NASDAQ: VPHM).   As a result of the ... Shire expects to complete the tender offer on January 24, 2014 ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... YORK, Feb. 15, 2012 Delcath Systems, Inc. (NASDAQ: ... ( Instituto Europeo di Oncologia – IEO) introduced ... a Feb. 15 press conference and discussed the status ... CHEMOSAT is a critical new treatment option for patients ...
... ERT (NASDAQ: ERT ) announced today that it ... year 2011 Monday, February 27, after the market closes. After ... 5:00 PM ET that day. For the conference ... United States or 1-412-858-4600 when calling internationally. There will be ...
Cached Medicine Technology:Delcath CHEMOSAT Presented as Innovative Treatment for Liver Metastases by European Institute of Oncology 2Delcath CHEMOSAT Presented as Innovative Treatment for Liver Metastases by European Institute of Oncology 3Delcath CHEMOSAT Presented as Innovative Treatment for Liver Metastases by European Institute of Oncology 4ERT to Report Fourth Quarter and Full Year 2011 Operating Results 2
(Date:4/24/2014)... detailed atlas with environment and health maps at a ... by the UK Small Area Health Statistics Unit (SAHSU), ... based at Imperial College London, the open-access atlas allows ... study the geographical pattern of 14 diseases and conditions ... and low birth weight. Alongside this it provides maps ...
(Date:4/24/2014)... have identified a way to sensitise cancer cells to ... The study published today in Cell Reports , ... to target cells that have become resistant to treatment. ... the possible mechanisms behind resistance to chemotherapy drugs like ... , Dr Andrew Gilmore, who led the research team ...
(Date:4/24/2014)... April 24, 2014 ,Take me out to the ... and kale chips. The more likely culprits include French ... , Unfortunately for children who play youth baseball, eating ... to weight problems, according to researchers at Wake Forest ... online edition of Childhood Obesity , found that ...
(Date:4/24/2014)... aspects, the corresponding terminology, and the relevance of ... in publications on randomized controlled trials (RCTs). This ... German Institute for Quality and Efficiency in Health ... final report. , Together with external experts, IQWiG ... glioblastoma, lung cancer, malignant melanoma, and pancreatic cancer. ...
(Date:4/24/2014)... 4/24/14) Dartmouth has been awarded one of 30 ... as a Lead Academic Participating Site in its new ... recipients are a select groups of investigators charged with ... cooperative groups., The NCTN grant system reflects recommendations from ... streamlines operations to achieve four goals:, Faster ...
Breaking Medicine News(10 mins):Health News:New high-detail atlas offers tool to explore local environment and health 2Health News:New high-detail atlas offers tool to explore local environment and health 3Health News:Scientists find way to target cells resistant to chemo 2Health News:Take the bat, leave the candy 2Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3
... 2, 2010 With the mutual goal of ... Pharmacopeial Convention (USP) and the Ukraine Scientific Pharmacopoeial ... have entered into an agreement to share standards ... medicines. Specifically, the Centre will have a five-year, ...
... (Zometa) can help fight metastatic breast cancer when given before ... St. Louis. When the drug was given along with ... the number of women who had tumor cells in their ... was published in the May issue of The Lancet ...
... In the largest study to date of a rare and ... in Detroit found radiation therapy may not improve a patient,s ... the bladder was poor, the study revealed several factors that ... 60 or younger, and having cystectomy, a procedure that either ...
... The current problems of access, affordability and quality in ... health insurance to all. The editors of the new ... propose an engineering approach to healthcare. In this publication ... A. Cortese and a team of highly regarded thought ...
... at age 40 in this group , WEDNESDAY, June 2 ... at higher risk of developing prostate cancer than white men, ... to be more likely to develop aggressive forms of the ... blacks and 64 whites -- whose prostates were removed at ...
... ... repository in IHE , ... Shawnee, Kan. (Vocus) -- Perceptive Software , creator of enterprise content management ... (IHE) Connectathon, held in Boardeaux, France., , , , ,IHE is an initiative by ...
Cached Medicine News:Health News:US, Ukraine agree to share standards for quality of medicines 2Health News:Bone drug suppresses wandering tumor cells in breast cancer patients 2Health News:Radiation does not improve survival for rare, invasive bladder cancer 2Health News:Perceptive Software Announces Successful Participation in Integrating the Healthcare Enterprise (IHE) Connectathon 2
... Our variable volume Finnpipette ... in a high performance pipette. ... colour-coded volume range, ensures quality, ... identification of the volume range ...
A Biplane Pediatric TEE transducer....
Super High Density, multi-frequency, convex array transducer for scanning during craniotomies. Same footprint as the UST-987-7.5 but with stronger penetration for deep cavernous tumors and other deep...
... Super High Density, multi-frequency, linear ... the first company to introduce ... and, as a result, changed ... and true workhorse has withstood ...
Medicine Products: